Table 5.
Adjusted relative risk of ESRD by increasing cumulative lifetime dose of analgesic use (all analgesics together).
| Grams | Cases | Controls | OR (95% CI) |
| Low use | 546 | 2030 | 1.00 (referent) |
| -500 | 278 | 1365 | 0.75 (0.64–0.88) |
| 501–1000 | 41 | 133 | 1.10 (0.77–1.59) |
| 1001–1500 | 10 | 47 | 0.76 (0.38–1.52) |
| 1501–2000 | 6 | 19 | 1.03 (0.40–2.62) |
| 2001–2500 | 4 | 9 | 1.50 (0.48–4.74) |
| 2501–3000 | 3 | 8 | 1.35 (0.37–4.94) |
| 3001 + | 19 | 11 | 6.02 (2.83–12.81) |
Categorical modeling for dose-response analyses. Odds ratios and 95% confidence intervals. Analysis based on index date 3 (5 years before start of dialysis), adjusted for age, sex, country. ORs were not calculated if the frequency in any group was less than 10 per cell: no data (n.d.) in the table. Standard reference group of low use is defined as exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime.